EUVIMEDScopri EUVIMED
EUVIMED · CrossrefJournal

Future Oncology

ISSN 1479-6694 · Informa UK Limited

Latest articles

  1. Treatment outcomes of tucatinib in combination with trastuzumab and pertuzumab as a maintenance therapy for people with HER2+ metastatic breast cancer: a plain language summary of findings from HER2CLIMB-05

    Veronique Dieras, Giuseppe Curigliano, Miguel Martin, Florence Lerebours, Junji Tsurutani, Marie-France Savard, Katarzyna J. Jerzak, Xichun Hu, Luciana Carla Martins de Aquino Pimentel, Ciara C. O’Sullivan, Eriko Tokunaga, Alicia Okines, Chiun-Sheng Huang, William Jacot, Joohyuk Sohn, Eduardo Cronemberger Silva, Volkmar Muelle, Shan Yang, Giovanna Granata, Qi Shen, Erika Hamilton

    Published: 2026-11-06DOI: 10.1080/14796694.2026.2753928

  2. Study design of the phase III ADELA trial of elacestrant with or without everolimus in ESR1 -mutated ER+/HER2– advanced breast cancer after progression on endocrine therapy plus a CDK4/6 inhibitor

    José Manuel Pérez-García, Antonio Llombart-Cussac, Elena López-Miranda, Alfonso Cortes, Isabel Garcia-Fructuoso, Elena Galve-Calvo, Manuel Ruiz-Borrego, Alba Cochs, Antonia Perelló-Martorell, Serafin Morales, Laia Boronat Ruiz, Sara Marín-Liébana, Cristina Saavedra, Isabel Blancas, Carmen Hinojo, Mariana López Flores, Sylvain Ladoire, Peter Schmid, Gilles Freyer, Rui Rui Zhang, Daniel Alcalá-López, Juliana Carvalho-Santos, Olga Boix, Carlos H. Barrios, Giuseppe Curigliano, Rupert Bartsch, Anne Clair Hardy Bessard, Tomer Wasserman, Javier Cortés

    Published: 2026-10-31DOI: 10.1080/14796694.2026.2753794

  3. Treatment outcomes and quality of life with palbociclib in patients with advanced breast cancer who also have other medical conditions: a plain language summary of findings from POLARIS

    Debu Tripathy, Joanne L. Blum, Meghan S. Karuturi, Steven McCune, Sobha Kurian, Mehdi M. Moezi, Daniel M. Anderson, Yan Ji, Timothy J. Pluard, John Migas, Shailendra Lakhanpal, Erin Jepsen, Yao Wang, Monica Z. Montelongo, Zhe Zhang, Joseph C. Cappelleri, Eric Gauthier, Gabrielle B. Rocque

    Published: 2026-10-08DOI: 10.1080/14796694.2026.2747581

  4. Study protocol of a prospective, non-interventional cohort study evaluating the benefits of transjugular intrahepatic portosystemic shunt in patients with hepatocellular carcinoma receiving first-line atezolizumab plus bevacizumab (NISTIPS TRITICC-4, IKF092)

    Carolin Angendohr, Christian Weigel, Anselm Kunstein, Markus Joerdens, Thorsten Goetze, Salah-Eddin Al-Batran, Bianca Zäpf, Maria Gonzalez-Carmona, Cennet Sahin, Marie-Luise Berres, Friedrich Foerster, Najib Ben Khaled, Christine Koch, Arne Kandulski, Henning Wege, Jonel Trebicka, Leonie S. Jochheim, Michael T. Dill, Christoph Springfeld, Severin Daum, Christoph Treese, Ursula Ehmer, Tom Luedde, Johannes Bode, Christoph Roderburg

    Published: 2026-10-08DOI: 10.1080/14796694.2026.2748246

  5. Plain language summary: comparing ivonescimab plus chemotherapy with placebo plus chemotherapy in people with advanced EGFR-mutated non–small cell lung cancer (NSCLC) whose disease worsened on EGFR-TKI treatment in the HARMONi study

    Xiuning Le, Antonio Passaro, Yuanyuan Zhao, Yan Huang, Janessa Laskin, Delvys Rodriguez-Abreu, Antonio Calles, Lyudmila Bazhenova, Giuseppe Lo Russo, Natasha B. Leighl, Federico Cappuzzo, Nicolas Girard, Sanjay Popat, Wenfeng Fang, Yongzhong Luo, Zhiyong He, Hui Zhao, Mingjun Li, Qibin Song, Hongyun Zhao, Haidar El Darsa, Isabelle Monnet, Manuel Cobo Dols, Rosario García Campelo, Robert Jotte, David Berz, Alexander Spira, Maurice Pérol, Misako Nagasaka, Howard West, Jianling Li, Fong Clow, Amy C. Moore, Jonathan Goldman, Zhang Li

    Published: 2026-10-08DOI: 10.1080/14796694.2026.2749355

Volumes

2026 · 2762025 · 3752024 · 3082023 · 2422022 · 4142021 · 4452020 · 3302019 · 3932018 · 3262017 · 3152016 · 3082015 · 3882014 · 2962013 · 2362012 · 1822011 · 1592010 · 1952009 · 1722008 · 932007 · 822006 · 832005 · 98

Conoscenze adatte al tuo lavoro.

Dall’inizio gratuito alla ricerca bibliografica personale, fino alla Research Suite completa.

Visualizza tariffe →

Sono inclusi tutti i testi integrali degli editori?

No. Citazioni, abstract e testi integrali sono contenuti diversi. La disponibilità dipende dalla fonte, dall’accesso aperto e dalle licenze esistenti. Un piano EUVIMED non sostituisce diritti aggiuntivi degli editori.